Researchers Say Combination Of Lenvatinib And Pembrolizumab Showed “Compelling Efficacy” For Treatment Of Advanced Endometrial Carcinoma

MedPage Today  (3/26, Jenkins) reports researchers found in a phase 1b/2 trial that the combination of lenvatinib and pembrolizumab showed “compelling efficacy” for the treatment of “advanced endometrial carcinoma, regardless of tumor microsatellite instability status.” The researchers found “a 38% objective response rate at 24 weeks among the 108 women with advanced endometrial carcinoma treated […]

Read More